ImmuCell Corporation (ICCC)
ImmuCell Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
ImmuCell Corporation (ICCC) is a Biotechnology company based in US with a market capitalization of $101.3M. Revenue grew 4.3% year-over-year and the company generated $1.2M in free cash flow. This page tracks ICCC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 69 employees · IPO May 5, 1987
Valuation
Valuation & price
$8.92as of May 17, 2026· -23.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.74
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$101.3M
Market cap
4.3%
Revenue growth (YoY)
41.4%
Gross margin
$1.2M
Free cash flow (USD)
$9.4M
Net debt
10.5%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $0.21)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 9, 2026Filing
Earnings Release
- 8-K eventJun 17, 2026Filing
Annual Meeting Results
- 8-K eventJun 10, 2026Filing
Manufacturing Capacity Expansion
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventMay 14, 2026Filing
Earnings Release
- Annual reportMay 13, 2026Filing
10-K Filed
- 8-K eventMay 8, 2026Filing
Settlement Agreement
- 8-K eventApr 14, 2026Filing
Board Changes
- 8-K eventApr 8, 2026Filing
Earnings Release
Questions
Frequently asked questions
What is ImmuCell Corporation's market cap?
ImmuCell Corporation (ICCC) has a market capitalization of $101.3M.
What is ICCC's P/E ratio?
A meaningful P/E ratio is not available for ICCC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ICCC's price-to-book (P/B) ratio?
ICCC trades at 3.74 times book value per share.
When did ImmuCell Corporation last report earnings?
ICCC last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying ICCC stock?
SEC Form 4 filings show no open-market insider buys at ImmuCell Corporation in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.